Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;20(2):631-633.
doi: 10.1007/s11739-024-03674-9. Epub 2024 Jun 13.

A therapeutic cooperation by bempedoic acid and proprotein convertase subtilisin/kexin type 9 inhibitors in statin intolerance inherited dyslipidemias

Francesco Sbrana  1 , Federico Bigazzi  2 , Carmen Corciulo  2 , Beatrice Dal Pino  2
Affiliations

A therapeutic cooperation by bempedoic acid and proprotein convertase subtilisin/kexin type 9 inhibitors in statin intolerance inherited dyslipidemias

Francesco Sbrana et al. Intern Emerg Med. 2025 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: No conflict of interest for each author. Ethics approval and consent to participate: Ethical approval was obtained. Human and animal rights: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

References

    1. Arca M, Celant S, Olimpieri PP, Colatrella A, Tomassini L, D’Erasmo L, Averna M, Zambon A, Catapano AL, Russo P (2023) Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in italy: a retrospective cohort study based on the AIFA monitoring registries. J Am Heart Assoc 12:e026550 - PubMed - PMC
    1. Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T (2017) Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: after PCSK-9 antibodies what else? Eur J Prev Cardiol 24:1528–1531 - PubMed
    1. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL (2020) Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 27:593–603 - PubMed
    1. Agarwala A, Quispe R, Goldberg AC, Michos ED (2021) Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside. Drug Des Devel Ther 15:1955–1963 - PubMed - PMC
    1. Rubino J, MacDougall DE, Sterling LR, Kelly SE, McKenney JM, Lalwani ND (2021) Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: a randomized, controlled trial. J Clin Lipidol 15:593–601 - PubMed

LinkOut - more resources